$ADMP The potential downside here is minimal while the upside is almost incalculable. Adamis is already undervalued, even without approval or a BO the price should be expected to increase over the coming months. The epipen shortage and the opioid crisis are both problems of which Adamis is a potential solution. I have $6000 in this that I don't plan to sell even after earnings or FDA approval, don't play with this company for quick profits, invest in it long term and you will be rewarded.
  • 2